Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis
Binoy Yohannan(The University of Texas Health Science Center at Houston), Eli Muchtar(Mayo Clinic), Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Shaji Kumar(Mayo Clinic), Prashant Kapoor, Amie Fonder, Moritz Binder(Mayo Clinic in Arizona), Yi L. Hwa, Yi Lin(Mayo Clinic), Rahma Warsame, Joselle Cook(Mayo Clinic), Matthew J. Rees(Mayo Clinic), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Mustaqeem Siddiqui(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Michelle Rogers(Mayo Clinic in Arizona), Suzanne R. Hayman, Angela Dispenzieri(Mayo Clinic), Miriam Hobbs, David Dingli
Cited by 18
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k